Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$3.22 USD
+0.02 (0.63%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $3.21 -0.01 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Nuvation Bio Inc. [NUVB]
Reports for Purchase
Showing records 1 - 20 ( 58 total )
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Taletrectinib Granted Orphan Drug Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nuvation Bio Inc.
Industry: Unclassified
Key Takeaways for ASCO 2024; Roundup for Covered Companies (Pt. 2)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
TRUST-I Data Released; Taletrectinib Looking Better and Better; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Updated Taletrectinib Data Expected at ASCO; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Taletrectinib to Bare More of its Talons at ASCO
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Nuvation Bio Inc.
Industry: Unclassified
Nuvation Goes After Augtyro With AnHeart Acquisition; Raising PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
Company: Nuvation Bio Inc.
Industry: Unclassified
First DDC Candidate to Enter Clinic in 2024; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R